Genomic analyses of bilateral testicular germ cell cancers (BITCOIN study) from the Italian Germ Cell Cancer Group (IGG).

S Sara Erika Bellomo (Candiolo Cancer Institute - FPO IRCCS, Candiolo (Torino), Italy) P Patrizia Giannatempo L Leonardo Tonelli (Candiolo Cancer Institute - FPO IRCCS, Candiolo (Torino), Italy) E Enrico Berrino (Pathology Unit, Candiolo Cancer Institute - FPO - IRCCS, Candiolo and Department of Medical Sciences, University of Turin, Candiolo (Torino), Italy) L Lorena De Zarlo (Candiolo Cancer Institute - FPO IRCCS, Candiolo (Torino), Italy) M Marco Maruzzo (Istituto Oncologico Veneto (IOV)–IRCCS, Padua, Italy) U Umberto Basso S Simona Secondino U Ugo De Giorgi (Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy) M Margaret Ottaviano (Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy) G Giovannella Palmieri F Fabrizio Di Costanzo (University of Naples "Federico II", Naples, Italy) F Francesca Pasi (Department of Oncology - Comprenesive Cancer Center Fondazione IRCCS Policlinico San Matteo, Pavia, Italy) L Laura Cattaneo (Advanced Diagnostics Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) C Caterina Marchiò (Department of Medical Sciences, University of Turin and Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Torino), Torino, Italy) P Pasquale Rescigno (The Institute of Cancer Research, London, United Kingdom)

Abstract

617 Background: Despite Testicular Germ Cell Tumors (TGCT) being the most common malignancy in young men aged 15 to 44 years, bilateral TGCT (bTGCT) accounts for 2–5% of TGCT cases. To date there are only small case reports exploring genomic aberrations in bTGCT, with no shared single nucleotide variants or structural chromosomal rearrangements identified in paired TGCTs, suggesting they develop independently. Methods: BITCOIN is an ambispective translational study that recruited 53 patients with bTGCT within 6 Italian Canters of Reference for TGCTs. We collected FFPE tissue specimens of both tumors (29 pts), or from one of those (14 pts) along with a blood sample when feasible (43 pts). Illumina Stranded Total RNA sequencing was performed to generate 100 bp-paired reads that were aligned to hg38 human genome using HISAT2. Raw gene-level counts, obtained with FeatureCounts algorithm, were then filtered for low expression, and normalized using TMM method for downstream differential expression analysis (DGE) via edgeR. Visualization of differentially expressed genes (FDR < 0.05 and logFC > 1.5) and gene set enrichment (GSE) analysis were carried out with ggplot2 and clusterProfiler, respectively. Results: Overall, in this preliminary analysis, 57 samples were sequenced from 30 unique pts. Of these, 27/57 (47%, representing 19 unique pts) reached at least 30 million reads and >50% of reads assigned to features. Notably, mean age of these specimens was 8 years. We identified among the bTGCT most expressed genes, embryonic/stem-like TGCT signatures (i.e. NR6A1 and BCN2 ) together with epigenetic regulators ( KMT2C, ARID1B ) and lncRNA drivers ( MALAT1 , NEAT1 , FTX , XACT ). DGE analysis was performed on 8 pts with paired tumors and 11 pts for whom only one tumor sample was available, highlighting differentially expressed genes according to the site (right [R] vs left [L]). Among these, APOB was the main marker of L localization. Finally, GSE using the Hallmark gene sets revealed a mild enrichment of epithelial-mesenchymal transition and TNFA signaling via NFKB (NES > 0.5 and FDR < 0.01 for both) in the L side. Conclusions: To date this represents the largest study on bTGCT. In this preliminary analysis, we demonstrate the feasibility of RNAseq on archival FFPE tissues identifying possible genomic characteristics of bilateral cancers.

Article Details

Volume / Issue Vol. 44, Issue 7_suppl
Published March 01, 2026
Pages 617-617
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (16)

S

Sara Erika Bellomo

Candiolo Cancer Institute - FPO IRCCS, Candiolo (Torino), Italy

P

Patrizia Giannatempo

L

Leonardo Tonelli

Candiolo Cancer Institute - FPO IRCCS, Candiolo (Torino), Italy

E

Enrico Berrino

Pathology Unit, Candiolo Cancer Institute - FPO - IRCCS, Candiolo and Department of Medical Sciences, University of Turin, Candiolo (Torino), Italy

L

Lorena De Zarlo

Candiolo Cancer Institute - FPO IRCCS, Candiolo (Torino), Italy

M

Marco Maruzzo

Istituto Oncologico Veneto (IOV)–IRCCS, Padua, Italy

U

Umberto Basso

S

Simona Secondino

U

Ugo De Giorgi

Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy

M

Margaret Ottaviano

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy

G

Giovannella Palmieri

F

Fabrizio Di Costanzo

University of Naples "Federico II", Naples, Italy

F

Francesca Pasi

Department of Oncology - Comprenesive Cancer Center Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

L

Laura Cattaneo

Advanced Diagnostics Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

C

Caterina Marchiò

Department of Medical Sciences, University of Turin and Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Torino), Torino, Italy

P

Pasquale Rescigno

The Institute of Cancer Research, London, United Kingdom